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Objective: Comprehensive outcome assessment of children receiving cardiac extra-
corporeal life support.
Methods: From 2000 to 2004, 39 consecutive children (aged 1 day to 4.4 years) had
cardiac extracorporeal life support. Neurodevelopmental follow-up of all survivors
was performed more than 6 months after life support (aged 536 12 months). Devel-
opmental delay was defined as a score of less than 70 on the Bayley Scales of Infant
Development II or Wechsler Preschool and Primary Scale of Intelligence. Predictor
variables for mortality (at 2 years’ follow-up) and delay were examined by univariate
and multivariate analyses.
Results: Indications for extracorporeal life support were progressive low cardiac out-
put in 14 (36%), failed weaning from cardiopulmonary bypass in 13 (33%), cardiac
arrest in 9 (23%), and hypoxia in 3 (8%). Cardiac anatomy was single ventricle in
16 (41%), biventricular in 21 (54%), and myocarditis in 2 (5%). Survival was 18
(46%) at hospital discharge and 16 (41%) at 2 years. In survivors, mental score
was 73 6 16 (normal 100 6 15), and 8 (50%) had mental delay. Initiating extracor-
poreal life support during cardiopulmonary resuscitation and duration of this resusci-
tation were not associated with death or mental delay. On multivariable Cox
regression, lactate on admission to the pediatric intensive care unit (hazard rate
1.13; 95% confidence intervals 1.08–1.27) and single ventricle anatomy (hazard
rate 3.93; 95% confidence intervals 1.62–9.49) were associated with death at 2 years.
Stepwise multiple regression found time for lactate to normalize on extracorporeal life
support, highest inotrope score during 120 hours of life support, and chromosomal ab-
normality explained 76.7% of the variance in mental score.
Conclusion: Cardiac extracorporeal life support had a 41% 2-year survival. Poten-
tially modifiable variables (time for lactate to normalize and highest inotrope score
early during extracorporeal life support) explained 69% of mental score variance.
E
xtracorporeal life support (ECLS) has become an accepted therapeutic modal-
ity for neonates and children with progressive respiratory and/or cardiac fail-
ure that is refractory to conventional management.1 The first use of ECLS to
provide cardiac assistance after surgery for congenital heart disease was reported in
1970, but since the early years of ECLS, the predominant application has been for
neonatal respiratory failure.2 Over the past decade, however, there has been a signif-
icant increase in the use of cardiac-related ECLS reported to the Extracorporeal Life
Support Organization international registry. Currently, ECLS is used as a bridge to
recovery in patients with severe low cardiac output syndrome after surgery for con-
genital heart disease and in nonsurgical conditions such as myocarditis and dysrhyth-
mias. As well, ECLS is used as a bridge to cardiac transplantation in children with
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DAbbreviations and Acronyms
CI 5 confidence intervals
CPB 5 cardiopulmonary bypass
CPR 5 cardiopulmonary resuscitation
ECLS 5 extracorporeal life support
HR 5 hazard rate
MAHSC 5 The Multiattribute Health Status Classification
System
OR 5 odds ratio
PICU 5 pediatric intensive care unit
SD 5 standard deviation
cardiomyopathy and patients who have not had significant re-
covery of cardiac function postoperatively.
More than 20,000 neonates worldwide have undergone
ECLS for respiratory failure in the past 20 years, and many
publications are available regarding the outcome of these ne-
onates.1 These data reveal an overall survival of approxi-
mately 75% with an incidence of long-term neurologic
dysfunction in survivors of between 15% and 30%.3-5 Less
than half as many neonates and children worldwide have
received ECLS for cardiac indications,1 with some recent sin-
gle-center reports of survival between 30% and 55% (overall
40%).6-8 The long-term neurodevelopmental outcomes of
these cardiac ECLS patients have not been widely studied, al-
though some series have described an incidence of long-term
neurologic deficits in 40% to 60% of survivors.9-11
Our objective was to evaluate the long-term neurodevelop-
mental outcome in young patients receiving cardiac-related
ECLS over a 5-year period and to identify any predictors of
adverse neurologic outcomes or death in these patients.
Patients and Methods
This study uses data from an interprovincial inception cohort out-
comes study conducted in three provinces in Western Canada. All
patients under 5 years of age who received ECLS from January
2000 through December 2004 were identified at the time of
ECLS. In all cases, ECLS was performed at the Stollery Children’s
Hospital, Edmonton, Alberta, Canada.
Demographic and some overall hospitalization variables that
were previously agreed on were collected prospectively.12 Several
pre-ECLS, ECLS, and post-ECLS variables (Table E1) were added
to the database by retrospective chart review. Long-term follow-up
was discussed with parents or guardians once survival was probable.
With their consent, contact was made with their respective follow-
up clinics at the tertiary site of origin.
Patients
All consecutive patients given venoarterial cardiac-related ECLS at
an age of less than 5 years over the 5-year period were registered.
There were no exclusion criteria. All survivors received multidisci-
plinary neurodevelopmental assessments through existing neonatal
follow-up clinics in Edmonton and Calgary, Alberta; Regina andThe Journal of ThorSaskatoon, Saskatchewan; and Winnipeg, Manitoba. Ethics board
approvals were obtained from each site before onset of the study.
All parents or guardians signed individual consent forms.
Early Childhood Assessments
Outcomes assessment was completed at least 6 months after ECLS.
At assessment, a research nurse recorded history of hospitalizations,
illnesses, medication use, and need for supplemental oxygen. Phys-
ical measurements were obtained as has been described.12 The fam-
ily socioeconomic status was determined by the Blishen Index,
a formula considering the relative income, needed education, and
prestige factor of employment with a population mean and standard
deviation (SD) of 43 (13).13 Maternal education was indicated by
years of schooling. Pediatricians experienced in neurodevelopmen-
tal follow-up examined each child for evidence of cerebral palsy14 or
visual impairment, defined as corrected visual acuity in the better
eye of less than 20/60.12 Hearing was evaluated by experienced cer-
tified pediatric audiologists in soundproof environments, as has
been described.12 Hearing impairment was defined as binaural sen-
sorineural hearing loss of more than 40 dB hearing level at any fre-
quency from 250 to 4000 Hz for children under 2 years; for older
children, bilateral responses greater than 25 dB hearing level within
the same frequencies were considered impaired. Motor or sensory
disability was defined as cerebral palsy, visual impairment, or sen-
sorineural hearing impairment as defined herein. Certified pediatric
psychologists and psychometrists administered The Bayley Scales
of Infant Development II in those assessed at 42 months of age or
less (n5 5).15 This is a widely accepted standardized outcome mea-
sure used in neonatal follow-up clinics yielding a mental standard-
ized score (developmental quotient) with a mean of 100 and an
SD of 15. A developmental quotient of less than 70 (2 SD below
the mean) indicates mental delay. Within a normative sample,
2.27% of children have scores of less than 70. The full scale intelli-
gence quotient of the Wechsler Preschool and Primary Scale of In-
telligence (third edition16) was used for those assessed after 48
months of age. This is a widely accepted standardized score with
a mean of 100 and an SD of 15.16 An intelligence quotient of less
than 70 (2 SD below the mean) indicates mental delay. The parent
completed Adaptive Behavior Assessment System, second edition,
for children before the sixth birthday. General Adaptive Composite
score with a mean of 100 and an SD of 15 was used to support the
tested findings. The Multiattribute Health Status Classification Sys-
tem (MAHSC) parental questionnaire with each of 8 domains coded
as normal or abnormal was recorded.
Statistics
Demographic variables included age at time of ECLS, weight on ad-
mission to the pediatric intensive care unit (PICU), gender, chromo-
somal abnormality, socioeconomic status, and mother’s year of
schooling. Pre-ECLS variables included the following: cardiac diag-
noses, cardiopulmonary resuscitation (CPR), seizure, plasma lac-
tate, inotrope score,17 pediatric logistic organ dysfunction score,18
cardiopulmonary bypass (CPB) time, aortic crossclamp time, and
deep hypothermic circulatory arrest time for those having cardiac
surgery before ECLS, whether ECLS was used after cardiac surgery
or not, and indication for ECLS (failure to wean off CPB in the op-
erating room, progressive low cardiac output syndrome, progressive
low cardiac output syndrome with refractory hypoxia, or ongoing
failed CPR). ECLS variables were recorded daily for up to 120 hoursacic and Cardiovascular Surgery c Volume 136, Number 4 977
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Dof ECLS support. They included cannulation site, left-sided vent,
use of a hemofilter for renal dialysis, plasma lactate (including the
time for lactate to return to normal levels # 2 mmol/L, inotrope
score, pediatric logistic organ dysfunction score, blood flow on
ECLS, fluid balance on ECLS, amount of packed red blood cells
and platelet transfusions, plasma free hemoglobin, seizures, and
the duration of ventilation and hospitalization. The primary out-
comes of interest were the survival and mental score. The secondary
outcomes included health and growth measures of morbidity, in-
cluding height, weight, head circumference, use of supplemental
oxygen, special diet or gastrostomy tube, long-term cardiac or pul-
monary medication, and behavioral concerns.
The patients were divided into three groups for descriptive pur-
poses: single ventricle anatomy, biventricular anatomy, and myocar-
ditis. For comparison of groups, the c2 test and Fisher exact test
(2-sided) were used. Bonferroni correction was applied. Forward
multivariable Cox regression was used to examine which variables
significant at a P value of# .10 on univariate analysis were predic-
tive of death by 2 years. For death by 10 days, given the short fol-
low-up time, we used multiple logistic regression. Forward
multiple logistic regression was also used to examine which vari-
ables significant at a P value of # .10 on univariate analysis were
predictive of mental delay. Sequential stepwise multiple regression
was used to explore the overall greatest proportion of mental score
outcome explained by a combination of predictors to a significance
level of .05. SAS version 9.1 (SAS Institute, Inc, Cary, NC) was
used for analyses.
Results
Description of Cohort
Thirty-nine patients had cardiac-related ECLS. The patients
having cardiac surgery before ECLS were 31 (3.0%) of the
1025 total patients under 5 years old having cardiac surgery
with CPB in the study time period. There were 16 (41%) pa-
tients with single ventricle anatomy, including 13 with hypo-
plastic left heart syndrome. There were 21 (54%) with
biventricular anatomy, including transposition of the great ar-
teries (n5 4), total anomalous pulmonary venous connection
(n 5 6), and other lesions (n 5 11). There were 2 (5%) with
myocarditis. Complete follow-up data were available for all
patients. With Bonferroni correction, demographic, pre-
ECLS, and ECLS variables showed no statistically signifi-
cant differences among the three groups (Table E1).
Description of the Outcomes
Survival outcomes are shown in Table 1. The survival to hos-
pital discharge was 18 (46%) of 39, and the 2-year survival
was 16 (41%) of 39. Twenty-two (56%) patients survived
to be decannulated from ECLS. There were no statistically
significant differences in mortality among the three groups
of patients (Table 1).
We found no adverse outcome in 7 (18%), disability in 9
(23%), and death by 2 years in 23 (59%) of this cohort. Gen-
eral health outcomes in the 16 long-term survivors are shown
in Table 2. Cerebral palsy occurred in 2 (12.5%) of the 16.
Poor growth, long-term pulmonary medication, and long-978 The Journal of Thoracic and Cardiovascular Surgery c Octterm cardiac medication were not uncommon. Fourteen
(88%) of the 16 survivors had behavioral concerns: behav-
ioral abnormalities were noted by physicians in 10 (62.5%)
of 16 survivors; parents reported behavioral concerns on
theMAHSC in 11 (69%) of the 16. There were no statistically
significant differences in these outcomes among the three
groups of patients (Table 2).
Neurodevelopmental outcomes in the 16 long-term survi-
vors are shown in Table 3. Follow-up was achieved in all sur-
vivors and performed at a mean age of 536 12 months. The
mental score was 73 6 16 and ranged from less than 55 to
116, being significantly skewed to the left compared with
the normal population (Figure 1). The adaptive-behavioral
questionnaire completed by parents supports these tested re-
sults with a General Adaptive Composite score of 79 6 19.
There were no statistically significant differences in these
outcomes among the three groups of patients (Table 3). Par-
ents of many of the survivors had concerns on the MAHSC,
particularly in the areas of cognition and behavior; the single
ventricle survivors all had parental concerns in the areas of
mobility, emotion, and self-care (Table 3). Overall, 8
(50%) survivors had mental delay (mental score , 70); all
3 survivors with chromosomal abnormality had delay, and
5 (38%) of the 13 without chromosomal abnormality had de-
lay. In the 8 mentally delayed survivors, 1 had a score greater
than 3 SD below the mean and had del22q11.2; the other 7
had scores between 2 SD and 3 SD below the mean, 2 of
whom had a chromosomal abnormality (22 duplication,
Turner mosaic).
Prediction of the Outcomes: Univariate Analyses
A univariate Cox regression indicates the following variables
were associated with death by 2 years at a P value of # .10:
hospitalization days, lactate on admission to the PICU, plate-
lets given over the first 120 hours of ECLS (milliliters per ki-
logram per day), packed red blood cells given over the first
120 hours of ECLS (milliliters per kilogram per day), single
ventricle anatomy, ventilator days, pre-ECLS highest lactate,
admission weight, and seizures (Table 4). A univariate logis-
tic regression indicated that lactate on admission to the PICU
(odds ratio [OR] 1.12; 95% confidence intervals [CI] 0.99–
1.27; P 5 .084) and single ventricle anatomy (OR 8.17;
95% CI 1.41–47.22; P 5 .019) were associated with death
at 10 days or less at a P value of # .10. We also compared
dichotomous variables between survivors with and without
mental delay, and the only significant variable was chromo-
somal abnormality: 3 (43%) of 7 with delay versus 0 (0%)
of 9 without delay (P 5 .063). Finally, the continuous vari-
ables were examined for their correlation with the mental
score in the 16 survivors; correlations significant at the P ,
.10 level are shown in Table E2.
CPR before ECLS occurred in 3 (33%) of 9 who died by
10 days or less, 4 (29%) of 14 who died by 30 days or less,
and 7 (30%) of 23 who died by 2 years. This comparesober 2008
Lequier et al Surgery for Congenital Heart DiseaseTABLE 1. Survival outcomes of the 39 patients after cardiac-related ECLS at less than 4.5 years of age, by type of heart lesion
Total (n 5 39) Single ventricle (n 5 16) Biventricle (n 5 21) Myocarditis (n 5 2) c2 P value
Reason for coming off ECLS 6.584 .160
Withdrawal 17 (44%) 10 (63%) 6 (29%) 1 (50%)
Decannulation 21 (54%) 5 (31%) 15 (71%) 1 (50%)
Transplant 1 (3%) 1 (6%) 0 (0%) 0 (0%)
Death by # 10 days 9 (23%) 7 (44%) 2 (10%) 0 (0%) 6.625 .036
Death by hospital discharge 21 (54%) 12 (75%) 8 (38%) 1 (50%) 4.989 .083
Death by 2 y 23 (59%) 12 (75%) 10 (48%) 1 (50%) 2.884 .236
ELCS, Extracorporeal life support.Withdrawal refers to removal of ECLS with the expectation of death shortly thereafter; decannulation refers to removal of
ECLS with expectation of survival being likely without ECLS; and transplant refers to removal of ECLS after successful heart transplantation.CH
Dwith CPR before ECLS, occurring in 9 (30%) of 30, 8 (32%)
of 25, and 5 (31%) of 16 who were survivors at these time
points, respectively (P 5 not significant). Similarly, ECLS
was initiated during ongoing CPR in 2 (22%) of 9 with death
at 10 days or less, 3 (21%) of 14 with death at 30 days or less,
and 6 (26%) of 23 with death by 2 years, compared with 7
(23%) of 30, 6 (24%) of 25, and 3 (19%) of 16 who were sur-
vivors at these time points, respectively (P5 not significant).
The duration of CPR in the 12 patients who had CPR before
ECLS was not associated with death at 2 years: 306 20 min-
utes in deaths versus 30 6 25 minutes in survivors (P 5
.943). Moreover, CPR before ECLS with mental delay (2/
7; 39%) versus without mental delay (3/9; 33%; P 5 .999),
and CPR while initiating ECLS with mental delay (1/7;
14%) versus without mental delay (2/9; 22%; P . .2) were
not associated with mental delay. Finally, the duration ofThe Journal of ThorCPR was not significantly different in those with mental de-
lay or not (13.56 25.7 vs 5.86 11.2 minutes; P5 .45), and
the duration of CPR did not correlate with the mental score
(r520.208; P5 .74). Of the 5 survivors who had CPR be-
fore ECLS, 2 had a mental score of 55 to 69, 2 a score of 70 to
84, and 1 a score of 85 to 99.
Prediction of the Outcomes: Multivariate Analyses
To predict death by 2 years, we entered all variables signifi-
cant at P# .10 on univariate analysis (Table 4) into a forward
multivariable Cox regression. After adjustment for hospital
duration and single ventricle anatomy, lactate on admission
to the PICU was associated with death with a hazard rate
(HR) of 1.17 (95% CI 1.08–1.27) (P 5 .0001) (Table 4).
Patients with single ventricle anatomy died at about 3.9
times the rate of those without single ventricle anatomyTABLE 2. General health outcomes of 16 surviving children after cardiac ECLS at< 4.5 years of age, by type of heart lesion
Total (n 5 16)
Single ventricle
(n 5 4)
Biventricle
(n 5 11)
Myocarditis
(n 5 1) c2 P value
Spastic left hemiparesis 2 (13%) 1 (25%) 1 (9%) 0 (0%) 1.206 .547
Vision loss 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Sensorineural hearing loss
Bilateral 1 (6%) 1 (25%) 0 (0%) 0 (0%)
Unilateral 1 (6%) 0 (0%) 1 (9%) 0 (0%)
Epilepsy 1 (6%) 0 (0%) 1 (9%) 0 (0%)
Strabismus 2 (13%) 1 (25%) 1 (9%) 0 (0%)
Behavioral diagnosis by
Pediatrician 8 (50%) 1 (25%) 6 (55%) 1 (100%) 2.318 .677
Psychiatrist 2 (13%) 1 (25%) 1 (9%) 0 (0%)
Respiratory examination abnormal 6 (38%) 1 (25%) 5 (45%) 0 (0%) 1.164 .559
Length , 3rd percentile 2 (13%) 1 (25%) 1 (9%) 0 (0%)
Weight , 3rd percentile 3 (19%) 2 (50%) 1 (9%) 0 (0%)
Head circumference , 2 SD (Nellhause) 3 (19%) 2 (50%) 1 (9%) 0 (0%)
Vocal cord paralysis 2 (13%) 1 (25%) 1 (9%) 0 (0%)
Gastrostomy . 2 y 3 (19%) 1 (25%) 2 (18%) 0 (0%)
Supplemental continuous oxygen at . 4 y 1 (9%) 0 (0%) 1 (9%) 0 (0%)
Long-term pulmonary medication 4 (25%) 1 (25%) 3 (27%) 0 (0%) 0.364 .834
Long-term cardiac medication 9 (56%) 3 (75%) 6 (55%) 0 (0%) 1.870 .393
ELCS, Extracorporeal life support; SD, standard deviation.acic and Cardiovascular Surgery c Volume 136, Number 4 979
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DTABLE 3. Childhood neurodevelopmental outcomes after cardiac-related ECLS at less than 4.5 years of age, by heart lesion
Total (n 5 16)
Single ventricle
(n 5 4)
Biventricle
(n 5 11)
Myocarditis
(n 5 1) F or c2 P value
DQ or IQ 73 (16) 73 (29) 73 (12) 72 0.001 .970
Mental delay , 70 8 (50%) 3 (75%) 5 (46%) 0 (0%) 2.091 .352
ABAS GAC 79 (19) 76 (29) 78 (17) 95 0.719 .412
Motor and/or sensory disability
(with mental delay)
2 (12.5%) 1 (25%) 1 (9%) 0 (0%)
MAHSC, % abnormal
Sensation 5 (31%) 2 (50%) 3 (27%) 0% 1.19 .552
Mobility 8 (50%) 4 (100%) 4 (36%) 0% 5.818 .055
Emotion 9 (56%) 4 (100%) 4 (36%) 1 (100%) 5.657 .059
Cognition 13 (81%) 3 (75%) 2 (18%) 1 (100%) 0.336 .845
Self-care 7 (44%) 4 (100%) 3 (27%) 0% 7.135 .028
Pain 5 (31%) 2 (50%) 3 (27%) 0% 1.19 .552
Behavior 11 (69%) 3 (75%) 7 (64%) 1 (100%) 0.661 .719
General health 8 (50%) 4 (100%) 4 (36%) 0% 5.818 .055
ELCS, Extracorporeal life support; ABAS, The general adaptive composite score on the adaptive behavior assessment system 2nd edition; DQ, developmental
quotient, which is the mental developmental index on the Bayley Scales of Infant Development II; IQ, intelligence quotient, which is the full scale IQ onWechs-
ler Preschool and Primary Scale of Intelligence III; MAHSC, the multiattribute health status classification system, parent completed. Motor or sensory dis-
ability was defined as cerebral palsy, visual impairment, or sensorineural hearing impairment (see Methods).The Psychomotor Developmental Index (PDI)
from the Bayley Scales of Infant Development II was available for the 12 survivors assessed in the first 3 years of life, with a mean 66.2 6 16.3; median
64, range 49 to 94.(HR 5 3.93; 95% CI 1.62–9.49; P 5 .002). For death by 10
days, the multiple logistic regression model consisted of vari-
ables significant at P , .10 on univariate analysis. In the ad-
justed model, lactate on admission to the PICU (OR 1.23;
95% CI 1.03–1.47; P 5 .021) and single ventricle anatomy
(OR 24.98; 95% CI 2.01–310.14; P5 .012) were associated
with death by 10 days. To predict mental delay in the 16 sur-
vivors, we entered all dichotomous variables associated with
delay at P # .10 (chromosomal abnormality) and all contin-
uous variables significantly correlated with mental score at
Figure 1. Distribution of mental scores in the 16 survivors of car-
diac-related ECLS at less than 4.5 years of age. In a normal popu-
lation, the mean score is 100 and SD is 15. Mental delay is
considered a score 2 SD or more below the mean (#70). The
ECLS survivor scores are skewed to the left.980 The Journal of Thoracic and Cardiovascular Surgery c OctP # .10 (Table E2) into a forward multiple logistic regres-
sion. No variable was predictive of mental delay. Finally,
all these variables for mental delay were entered into a step-
wise multiple regression to predict the mental score as a con-
tinuous outcome. Three variables (time for lactate to fall to
# 2 mmol/L on ECLS, highest inotrope score during the first
120 hours of ECLS, and chromosomal abnormality)
explained 76.7% of the variance in the mental score outcome
(Table 5).
Discussion
Few reports describe the detailed survival and neurodevelop-
mental outcomes of patients receiving cardiac-related ECLS
at age less than 5 years.10 This study yields several important
findings. First, 18 (46%) of 39 survived to hospital discharge,
and the 2-year survival was 16 (41%) of 39. Second, neuro-
developmental concerns were identified in most survivors,
with a mean mental score of 73 6 16, mental delay in 8
(50%) of 16, motor or sensory disability in 2 (12.5%) of
16, and many having abnormal scores on theMAHSC. Third,
a significant minority of survivors have ongoing concerns in
general health (eg, growth, feeding, behavior, and pulmonary
and cardiac medications). Fourth, on multivariable analysis,
single ventricle anatomy and lactate on admission to the
PICU were associated with death at 10 days and 2 years;
and three variables (time for lactate to fall to # 2 mmol/L
on ECLS, highest inotrope score during the first 120 hours
of ECLS, and chromosomal abnormality) explained 77% of
the variance in mental score outcome. Finally, receivingober 2008
Lequier et al Surgery for Congenital Heart DiseaseTABLE 4. Univariate (significant at P < .10) and multivariable Cox regression analysis for death by 2 years after ECLS
Univariate analysis Multivariable analysis
Variable HR (95% CI) P value HR (95% CI) P value
Hospital weeks 0.10 (0.03–0.34) .0002 0.09 (0.02–0.32) .0002
Lactate on PICU admission 1.13 (1.05–1.21) .0005 1.17 (1.08–1.27) .0001
Platelets given
over 120 h of ECLS (mL $ kg21 $ d21)
1.03 (1.01–1.05) .0035 — —
PRBC given
over 120 h of ECLS (mL $ kg21 $ d21)
1.01 (1.00–1.01) .0054 — —
Single ventricle anatomy 2.50 (1.09–5.70) .0297 3.93 (1.62–9.49) .0024
Ventilator weeks 0.22 (0.05–0.88) .0326 — —
Pre-ECLS highest lactate 1.07 (1.00–1.14) .0576 — —
Admission weight (kg) 0.85 (0.71–1.03) .0907 — —
Seizures 1.52 (0.92–2.49) .0995 — —
ELCS, Extracorporeal life support; PICU; pediatric intensive care unit; PRBC, packed red blood cells; HR, hazard rate; CI, confidence intervals. Lactate on PICU
admission in 16 survivors 5 (3) mmol/L, and in 23 nonsurvivors 11 (6) mmol/L (P 5 .001).CH
DCPR before ECLS was not associated with death or a worse
mental score outcome.
The rate of survival to discharge from the hospital (46%) is
comparable with what has been reported in previous series of
cardiac ECLS patients.1,7-11We also showed a small (5%) ad-
ditional postdischarge mortality by 2 years after ECLS in this
cohort of patients. Risk factors for an adverse outcome in-
cluded single ventricle anatomy, chromosomal abnormality,
younger age, and lower weight. All of these factors have
been previously identified to be associated with increased
mortality when using cardiac ECLS and likely represent the
need for technically more complex surgical procedures and
more difficult recovery from low cardiac output syndrome
after CPB. Lactate concentrations are used clinically as an in-
dicator of tissue hypoxia and have previously been shown to
predict death and poor neurodevelopmental outcome in in-
fants receiving respiratory ECLS and in infants after surgery
for congenital heart disease.19,20 Onmultivariate analysis, we
found that lactate on admission to the PICU was predictive of
death.
TABLE 5. Stepwise multiple regression to predict the
mental score in 16 survivors of cardiac-related ECLS at
< 4.5 years of age
Variable
Adjusted
r2 b SE t Significance
Time for lactate
to fall to # 2 mmol/L
on ECLS (h)
.484 .278 .067 4.145 .001
Highest inotrope
score in first 120 h
on ECLS
.687 .539 .191 2.821 .015
Chromosomal
abnormality
.767 212.31 5.289 22.327 .038
SE, Standard error; ECLS, extracorporeal life support.The Journal of ThorThere are many potential causes of neurologic morbidity
in pediatric patients who require ECLS for circulatory sup-
port. First, central nervous system abnormalities have been
described in patients with congenital heart disease both be-
fore and after surgery.12,21 Pre- ECLS events such as pro-
found hypoxia and hypotension may occur before, during,
or after surgery for congenital heart disease. The CPB tech-
niques used (hypothermia, circulatory arrest, low-flow by-
pass, and anticoagulation with heparin) can contribute to
postoperative neurologic morbidity.22 ECLS-specific risks
include ligation of the carotid artery and jugular vein, cere-
bral hemorrhage associated with altered cerebral autoregula-
tion and prolonged systemic heparinization, microthrombi
from the ECLS circuit, and any potential exposure to toxic
agents.23
Our data indicate that over half (9/16 5 56%) of long-
term survivors of cardiac ECLS have neurologic morbidity.
It is encouraging that 7 of the 16 surviving patients were
found to have no disability, but this is only 18% of the total
patients who received cardiac ECLS. Chow and associates9
reported that half of their long-term survivors of cardiac
ECLS had adverse neurologic outcomes, determined by pa-
rental questionnaire rather than detailed neurodevelopmental
testing; this resulted in only 17% of their patients who re-
ceived cardiac ECLS ultimately surviving without neurologic
morbidity. Hamrick and coworkers10 reported cognitive out-
comes of infants after cardiac ECLS. Of their 15 (28%) long-
term survivors, 3 (21%) had a mental score between 1 SD and
2 SD below average, and 4 (29%) had a mental score more
than 2 SD below average; this resulted in only 13% of their
patients surviving neurologically intact. Given the high mor-
tality rate reported in the literature for patients requiring car-
diac ECLS as well as the many potential causes of central
nervous system damage for these patients during their clini-
cal course, the outcomes described above are not unexpected.
We found that the potentially modifiable variables of time foracic and Cardiovascular Surgery c Volume 136, Number 4 981
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Dlactate to fall to equal to or less than 2 mmol/L on ECLS and
highest inotrope score during the first 120 hours of ECLS
could explain 68.7% of the variability in mental outcome.
This suggests that early attention to optimizing ECLS support
may result in less neurologic morbidity in survivors.
Interestingly, the need for CPR before ECLS was not as-
sociated with an increased incidence of death or neurologic
morbidity in our patients as it was in previous reviews of
the Extracorporeal Life Support Organization registry as
well as single-center series of cardiac ECLS patients.9,10,24
This may be due to the more common availability and use
of rapid response equipment and personnel in our center
and in recent series.25 As well, it has been shown that children
with isolated heart disease have an improved survival after
ECLS preceded by CPR when compared with those with
other medical conditions.26 This likely reflects a more revers-
ible myocardial depression in patients with isolated heart dis-
ease than in those children with more complex medical
conditions and multiple organ dysfunction syndrome. Simi-
larly, we did not show an increased incidence of death in
those patients who received renal replacement therapy during
ECLS. Classically, the need for renal replacement therapy af-
ter surgery for congenital heart disease or during the provi-
sion of cardiac ECLS implied significant secondary organ
dysfunction after periods of low cardiac output and was
a risk factor for mortality.27 Recently however, there has
been emphasis placed on earlier implementation of renal re-
placement therapy in critically ill children.28 We have adop-
ted more liberal application of renal replacement therapy
during ECLS, and this along with our relatively small number
of patients likely accounts for a lack of association with
death.
Our cohort included a significant number of patients with
single ventricle anatomy (41%). Historically, patients with
single ventricle anatomy have demonstrated lower rates of
survival than other cardiac ECLS patients.29 With the in-
creased use of cardiac ECLS for patients with single ventricle
anatomy over the past decade, their survivals have improved
and may rival age- and size-matched patients with biventric-
ular disease.30 We found patients with single ventricle anat-
omy who were treated with ECLS to have a significantly
higher 2-year mortality rate than patients with biventricular
disease. Many of our patients with single ventricle anatomy
had a Blalock–Taussig shunt; although we aimed for higher
than usual ECLS flows to provide the systemic and pulmo-
nary circulations in these patients, it is possible that the flows
were not adequate and contributed to mortality. This is un-
likely to account for the mortality difference inasmuch as
the patients with single ventricle disease had similar lactates
and inotrope scores compared with patients with biventricu-
lar disease.
Limitations of this report include the relatively small num-
ber of patients, which limits the power of any statistical anal-
ysis, and the retrospective collection of some of the acute care982 The Journal of Thoracic and Cardiovascular Surgery c Octvariables around the time of ECLS. Our patients did not have
complete neurologic examinations or neuroimaging before
being placed on ECLS; therefore, we could not examine
whether preoperative neurologic abnormalities contributed
to outcome. Strengths of this report include the inception co-
hort design with prospective complete and detailed neuro-
logic testing of all survivors with no loss to follow-up, and
the large amount of data available for analysis.
Although cardiac ECLS is a life-saving intervention, it is
associated with a significant risk of mortality and neurologic
morbidity. There is a need for vigilant surveillance of neuro-
logic and psychosocial performance in survivors and provi-
sion of necessary rehabilitative treatments. Our data suggest
that two potentially modifiable variables (time for lactate to
fall to# 2 mmol/L on ECLS and highest inotrope score dur-
ing the first 120 hours of ECLS) account for 69% of the var-
iance in mental outcome. Starting ECLS during ongoing CPR
was not associated with mortality or mental outcome. It is
hoped that future improvements in equipment, protocols,
and the application of ECLSwill translate into improved neu-
rologic outcomes in future cohorts of patients.
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DTABLE E1. Descriptive variables of 39 children with cardiac-related ECLS at < 4.5 years of age, by type of heart lesion
Total
(n 5 39)
Single ventricle
(n 5 16)
Biventricle
(n 5 21)
Myocarditis
(n 5 2) c2 or F P value
Gender: male 20 (51%) 7 (44%) 12 (57%) 1 (50%) .653 .721
Chromosomal abnormality* 4 3 1 0 2.171 .338
CPR before ECLS 2.681 .613
In OR 1 (3%) 1 (6%) 0 (0%) 0 (0%)
In PICU 1 (3%) 3 (19%) 7 (33%) 1 (50%)
Seizures 2.829 .587
Pre-ECLS 1 0 1 0
During ECLS 6 2 3 1
Re-CPB in OR 8 (21%) 4 (25%) 4 (19%) 0 (0%) .741 .690
Sternum open pre-ECLS 29 (74%) 14 (88%) 16 (71%) 0 (0%) 7.344 .025
Indication for ECLS 3.886 .692
Fail weaning 13 (33%) 7 (44%) 6 (27%) 0 (0%)
Hemodynamic 14 (36%) 4 (25%) 9 (43%) 1 (50%)
Hypoxia 3 (8%) 2 (13%) 1 (5%) 0 (0%)
CPR 9 (23%) 3 (19%) 5 (24%) 1 (50%)
Cannulation site 10.482 .033
Chest 17 (44%) 6 (38%) 11 (52%) 0 (0%)
Neck 20 (51%) 9 (56%) 10 (48%) 1 (50%)
Multiple 2 (5%) 1 (6%) 0 (0%) 1 (50%)
Left side vent 8/37 (22%) 4 (25%) 3 (16%) 1 (50%) 1.44 .487
Cardiac catheterization done 12 (31%) 5 (31%) 7 (33%) 0 (0%) .955 .620
Residual lesion 11 (28%) 4 (25%) 7 (33%) 0 (0%) 1.140 .566
Sternal exploration first 5 d 22 (56%) 7 (44%) 14 (67%) 1 (50%) .383
Hemofilter used 26 (67%) 10 (63%) 15 (71%) 1 (50%) .589 .745
Time of surgery in relation to ECLS
No surgery 1 (3%) 0 (0%) 0 (0%) 1 (50%)
Before 31 (80%) 14 (88%) 17 (81%) 0 (0%)
After 5 (13%) 2 (13%) 2 (10%) 1 (50%)
During 2 (5%) 0 (0%) 2 (10%) 0 (0%)
Age (d) ECLS started 206 (402) 203 (404) 215 (239) 120 (42) .049 .952
Admission weight (kg) 5.2 (3.3) 5.2 (3.6) 5.1 (3.2) 5.4 (.7) .010 .991
CPB time (min) 181 (122) 175 (86) 187 (145) 0 .082 .776
Aortic crossclamp time (min) 51 (41) 36 (28) 63 (45) 0 4.343 .045
DHCA time (min) 15 (19) 13 (18) 17 (20) 0 .507 .482
Inotrope score just before ECLS 34 (40) 28 (22) 40 (50) 15 (21) .671 .517
12 h prior 10 (17) 11 (16) 11 (20) 0 .361 .700
24 h prior 7 (12) 9 (12) 7 (14) 0 .471 .629
Lactate just before ECLS 13 (6.9) 11.2 (6.3) 14.8 (7.6) 11.6 (.1) .495 .615
Peak lactate on ECLS 11.1 (5.7) 9.6 (4.6) 12.5 (6.4) 8.7 (1.9) 1.431 .252
Time for lactate to fall to # 2 mmol/L (h) 28.9 (27.9) 30.8 (34.6) 26.3 (22.7) 40.5 (31.8) .286 .753
CPR duration before ECLS (min) (n5 12) 30 (21) 23 (16) 30 (21) 65 1.945 .199
Time for lactate to fall to # 5 mmol/L (h) 8.2 (8.8) 5.5 (6.5) 10.5 (10.2) 6.5 (3.5) 1.540 .228
ECLS duration (h) 119 (81) 102 (59) 134 (96) 96 (39) .761 .474
ECLS flow (mL $ kg21 $ min21)
At 12 h 108 (33) 120 (41) 100 (25) 101 (.7) 1.709 .195
24 h (n 5 38) 111 (37) 125 (45) 103 (29) 95 (7) 1.784 .183
Inotrope score at 24 h on ECLS 10.3 (15.4) 6.8 (8.2) 13.6 (19.3) 5.0 (7) 1.017 .372
Highest inotrope score in 120 h on ECLS 18.5 (17.4) 12.0 (12.7) 24.8 (19.0) 5.0 (7) 3.485 .041
Fluid balance at 24 h on ECLS
(mL/kg21/day21)
122 (126) 91 (133) 146 (124) 118 (66) .864 .430
Cumulative fluid balance over duration
of ECLS (mL/kg)
3.0 (4.1) 2.0 (4.3) 3.2 (4.2) 1.1 (.9) .232 .794
PRBC at 24 h on ECLS (mL/kg) 171 (160) 201 (217) 147 (112) 196 (126) .507 .607983.e1 The Journal of Thoracic and Cardiovascular Surgery c October 2008
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CH
DTABLE E1. Continued
Total
(n 5 39)
Single ventricle
(n 5 16)
Biventricle
(n 5 21)
Myocarditis
(n 5 2) c2 or F P value
PRBC average over 120 h on ECLS
(mL/kg21/day21)
118 (95) 123 (107) 118 (92) 78 (22) .487 .619
Platelets at 24 h on ECLS (mL/kg) 40 (39) 54 (56) 30 (20) 40 (6) 1.783 .183
Platelets average over 120 h on ECLS
(mL/kg21/day21)
31 (23) 36 (32) 28 (17) 27 (11) .438 .649
Plasma free Hb at 24 h on ECLS 321 (241) 307 (214) 320 (228) 450 (488) .301 .742
Highest plasma free Hb in 120 h on ECLS 931 (933) 783 (629) 1019 (1142) 1214 (593) .375 .690
Ventilator days 27 (29) 29 (38) 28 (20) 8 (6) .459 .635
Hospital days 48 (46) 49 (67) 50 (25) 33 (6) .114 .893
PELOD score just before ECLS 17 (7) 15 (5) 18 (9) 22 (1) 1.092 .346
PELOD score at 24 h on ECLS 17 (8) 17 (8) 17 (8) 24 (.7) .687 .510
Highest daily PELOD score over 120 h on
ECLS
20 (7) 20 (6) 20 (7) 28 (7) 1.377 .265
CPB, Cardiopulmonary bypass; CPR, cardiopulmonary resuscitation with chest compressions; DHCA, deep hypothermic circulatory arrest; ECLS, extracorpo-
real life support; Hb, hemoglobin; OR, operating room; PELOD, pediatric logistic organ dysfunction score; PICU, pediatric intensive care unit; PRBC, packed red
blood cell transfusion. *Chromosomal abnormalities were deletion 22q11.2 (1 single ventricle, 1 biventricular), Turner syndrome (1 with single ventricle), and
chromosome 22 duplication (1 with single ventricle).The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 983.e2
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DTABLE E2. Pearson product moment correlations of continuous variables with the mental score in 16 survivors on
cardiac-related ECLS at age < 4.5 years
Mental score
r P value
Age ECLS started (d) 0.467 .068
Admission weight (kg) 0.505 .046
Time for lactate to fall to # 2 mmol/L (h) 0.720 .002
Highest inotrope score in first 120 h on
ECLS
0.662 .005
PRBC at 24 h on ECLS 0.008 .084
ELCS, Extracorporeal life support; PRBC, packed red blood cell transfusion.983.e3 The Journal of Thoracic and Cardiovascular Surgery c October 2008
